Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Other
Enrollment
1,000actual
Sites
39
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-18 | actual | When the study began enrolling |
| Primary completion | 2025-09-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-03 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cough-Variant Asthma
Intervention
- Drug: Budesonide-Formoterol treatment — also filed as Budesonide 160 μg/formoterol 4.5 μg treatment
Primary outcome
what the primary-completion date above is the date OFTo obtain a cut-off value for FeNO which can be used to distinguish responsiveness to 8 weeks treatment of Budesonideformoterol (based on visual analog scale [VAS]).
measured 8 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed